Sanofi Aventis
FREE Daily Email Newsletter
Study: New Drug May Help Some Asthmatics
May 22, 2013 8:01 am | by By Andrew Pollack, New York Times News Service | News | CommentsA new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday. In the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, Dupilumab, compared with those getting a placebo.
Sanofi Fined for 'Smear Campaign' Against Generic Plavix
May 14, 2013 9:29 am | by Matthew Dennis | News | CommentsFrance's antitrust authority on Tuesday fined Sanofi 40.6 million euros ($52.6 million) for a "smear campaign" designed to limit sales of generic versions of Plavix. The ruling on the drug, which last year generated global sales of nearly 2.1 billion euros ($2.7 billion), follows a complaint by Teva.
Hospital to Probe East German Medical Trials
May 13, 2013 3:44 pm | by FRANK JORDANS,Associated Press | News | CommentsBerlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
Sanofi Earnings Slashed in First Quarter
May 2, 2013 2:52 am | by The Associated Press | News | CommentsFrench drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings. Sanofi's net profit was €1 billion ($1.3 billion) in the January-March quarter, down 45 percent from €1.8 billion...
Report Reveals Side Effects of Ambien
May 1, 2013 11:47 am | by CBS | Videos | CommentsA government report reveals dangerous side effects of the popular sleeping pill Ambien, and its generic versions. Between 2005-2010 there was a 220% jump in visits to the emergency room. Ambien and its generic version have 44 million prescriptions were filled last year.
Amyris Rises on Sanofi Malaria Drug News
April 12, 2013 7:55 am | News | CommentsShares of Amyris rose Thursday after Amyris' partner, Sanofi, started large-scale production of a malaria treatment using technology Amyris developed. Sanofi said it is beginning large-scale production of synthetic artemisinin, a key ingredient in malaria therapies. Artemisinin is derived from a wildflower called sweet wormwood, and it is the only effective medicine now widely used to cure malaria.
Sanofi Pasteur MSD Submits Quadrivalent Influenza Vaccine for European Licences
April 11, 2013 8:24 am | News | CommentsSanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, announced today that it has submitted a decentralized marketing authorization application in Europe for a ' Q uadrivalent' influenza vaccine, a new advanced seasonal flu vaccine.
Genzyme’s AUBAGIO® Approved in Argentina for the Treatment of Relapsing MS
April 8, 2013 9:42 am | News | CommentsGenzyme, a Sanofi company, announced today Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved once-daily, oral AUBAGIO® 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis (MS).
Sanofi Building New Factory in Vietnam
April 1, 2013 8:05 am | News | CommentsSanofi SA said Friday that it's building a new medicine factory in Vietnam to supply drugs to that country and others in the region. The move is part of a fast-growing trend among major international pharmaceutical companies to put factories and research centers in emerging markets that the industry increasingly is targeting for growth.
US Probes Sanofi Over Blockbuster Drug Plavix
March 12, 2013 8:11 am | by SARAH DiLORENZO,Associated Press | News | CommentsThe U.S. Justice Department is investigating drug maker Sanofi's disclosures to the Food and Drug Administration about different responses to its blockbuster blood thinner Plavix. The French company said in a filing with the Securities and Exchange Commission last week that it learned in June about the investigation.
DBV Technologies Enters into a Strategic Manufacturing Agreement with Sanofi
March 5, 2013 8:03 am | News | CommentsDBV Technologies, creator of the Viaskin® allergy treatment, announced today that it entered into a strategic manufacturing agreement with Sanofi to produce Viaskin’s Active Pharmaceutical Ingredients (API), such as the peanut protein extract. Per the agreement, Sanofi will act as DBV’s Contract Manufacturing Organization (CMO).
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey
March 4, 2013 7:59 am | News | CommentsMore than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
Regeneron Says Sanofi Plans to Buy More Stock
February 12, 2013 7:53 am | News | CommentsRegeneron Pharmaceuticals Inc. said Monday that the French drugmaker Sanofi, its partner on a recently approved cancer drug, intends to buy more shares of Regeneron stock. The Tarrytown, N.Y., company said it received a notice about the planned transaction from the Federal Trade Commission.
FDA Calling For Lower Doses of Ambien
January 11, 2013 3:13 am | Videos | CommentsThe FDA released new guidelines for the popular sleeping pill Ambien and drugs with the same active ingredient.
Sanofi-Aventis to Pay $109M Kickbacks Settlement
December 20, 2012 3:16 am | by The Associated Press | News | CommentsThe U.S. subsidiaries of French pharmaceutical giant Sanofi will pay $109 million to settle allegations they gave kickbacks to induce doctors to buy and prescribe Hyalgan, a knee injection.
Genzyme Receives European Label Expansion for Thyrogen
December 7, 2012 2:55 am | News | CommentsGenzyme, a Sanofi company, today announced it has received European Commission approval of a product label expansion for the use of Thyrogen®.
Selecta Biosciences and Sanofi Sign Global Collaboration to Develop Antigen-Specific Immunotherapies
November 29, 2012 3:08 am | News | CommentsSelecta Biosciences, Inc., a clinical-stage biopharmaceutical company, today announced that it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.
Analyst: Expect Diabetes Drug Market to See Strong Growth
October 12, 2012 3:58 am | News | CommentsNEW YORK (AP) — A Jefferies & Co. analyst said Thursday that sales of diabetes drugs should keep growing at a strong clip for the rest of the decade, reaching $65 billion a year in 2020.
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
October 3, 2012 4:32 am | News | CommentsSanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix® and Avapro®/Avalide® in many major markets
Sanofi and TB Alliance Announce Collaboration to Accelerate New Treatments Against Tuberculosis
September 21, 2012 4:14 am | News | CommentsSanofi and the Global Alliance for TB Drug Development have announced a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis.
FDA Approves Genzyme’s AUBAGIO®, a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis
September 13, 2012 4:09 am | News | CommentsGenzyme, a Sanofi company, announced today that the FDA has approved AUBAGIO® (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).
Early Test Suggests Dengue Vaccine Possible
September 11, 2012 4:06 am | by MARIA CHENG,AP Medical Writer | News | CommentsLONDON (AP) — Results from an early test of a dengue vaccine suggest it isn't ideal, but scientists say the study is still encouraging news in the global fight against the disease known as "break-bone fever."
Impax Laboratories Announces Settlement of Litigation with Genzyme
September 4, 2012 4:04 am | News | CommentsImpax Laboratories, Inc. today announced that it has reached agreement with Genzyme, a Sanofi company, to settle pending U.S. litigation with regard to the production and sale of generic formulations of RENVELA® (sevelamer carbonate 800 mg tablet and oral suspension 2.4g and 0.8g) and RENAGEL® (sevelamer hydrochloride 400 mg and 800 mg tablets).
Wockhardt to Launch Generic Version of BPH Drug Uroxatral
August 15, 2012 4:20 am | News | CommentsWockhardt has received final approval from the FDA for marketing 10mg extended release tablets of Alfuzosin hydrochloride, which is used in treatment of Benign Prostatic Hyperplasia or enlarged prostate. Alfuzosin is the generic name for the brand Uroxatral, marketed in the United States by Sanofi-Aventis.
FDA Clears Regeneron-Sanofi Colon Cancer Drug
August 6, 2012 4:28 am | News | CommentsNEW YORK (AP) — The Food and Drug Administration on Friday approved a new colorectal cancer drug developed by French drugmaker Sanofi and Regeneron Pharmaceuticals Inc.
